Monoclonal antibodies for renal diseases: Current concepts and ongoing treatments

Expert Opinion on Biological Therapy

Volumn 15, Issue 8, 2015, Pages 1119-1143

  Santoro, Domenico ^a   Pellicanò, Vincenzo ^a   Visconti, Luca ^a   Trifirò, Gianluca ^a   Cernaro, Valeria ^a   Buemi, Michele ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Glomerulonephritis; Monoclonal; Proteinuria; Renal disease

Indexed keywords

ABATACEPT; ADALIMUMAB; BELIMUMAB; CD20 ANTIGEN; COMPLEMENT COMPONENT C3; DACLIZUMAB; ECULIZUMAB; FRESOLIMUMAB; INFLIXIMAB; MILATUZUMAB; MONOCLONAL ANTIBODY; OCRELIZUMAB; RITUXIMAB; TOCILIZUMAB; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR;

ANTIGEN SPECIFICITY; B LYMPHOCYTE; CONGENITAL NEPHROTIC SYNDROME; DIABETIC NEPHROPATHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY DISEASE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; KIDNEY DISEASES; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD20; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; KIDNEY DISEASES; RITUXIMAB; TREATMENT OUTCOME;

EID: 84936943461     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1045870     Document Type: Review

References (70)

1. Pandey S. Hybridoma technology for production of monoclonal antibody. Int J Phar Sci Rev Res 2010;1(2):88-94
2. Frenzel L. Novel uses of rituximab. Rev Prat 2013;63(10):1349-53
3. Evans R, Salama AD. Update on rituximab: an established treatment for all immune-mediated kidney diseases? Nephron Clin Pract 2014;126:97-109
4. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11-21
5. Beck LH Jr, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011;22(8):1543-50
6. Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012;23:1416-25
7. Fervenza FC, Abraham RS, Erickson SB, et al. Mayo nephrology collaborative group: rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin J Am Soc Nephrol 2010;5:2188-98
8. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371(19):1771-80
9. Ruggenenti P, Ruggiero B, Cravedi P, et al. Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 2014;25(4):850-63
10. Dillon JJ, Hladunewich M, Haley WE, et al. Pilot study of rituximab for membranoproliferative glomerulonephritis (MPGN) rituximab therapy for Type I MPGN. Clin Nephrol 2012;77(4):290-5
11. Iijima K, Sako M, Nozu K, et al. Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroiddependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2014;384(9950):1273-81
12. Rovin BH, Furie R, Latinis K, et al. LUNAR Investigator Group: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64(4):1215-26
13. Lu Y-TT, Jonsdottir T, van Vollenhoven RF, Isenberg DA. Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases. Ann Rheum Dis 2008;67:330-4
14. Leone A, Sciascia S, Kamal A, Khamashta M. Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies. Expert Rev Clin Immunol 2015;11(1):109-16
15. Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Investig Drugs 2008;9(11):1206-15
16. Kausar F, Mustafa K, Sweis G, et al. Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther 2009;9(7):889-95
17. Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab, a humanized antiCD20 antibody, in patients with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III belong study. Arthritis Rheum 2010;62:1455
18. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10(1):45-65
19. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(3):711-15
20. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345(15):1098-104
21. U.S. Food and Drug Administration (FDA). "Infliximab Product Approval Information - Licensing Action", Retrieved
22. Morgan MD, Drayson MT, Savage CO, Harper L. Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin Pract 2011;117(2):c89-97
23. Cofiell R, Kukreja A, Bedard K, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015. [Epub ahead of print]
24. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355(12):1233-43
25. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009;360(5):544-6
26. Nürnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolyticuremic syndrome. N Engl J Med 2009;360(5):542-4
27. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368(23):2169-81
28. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011;364(26):2561-3
29. D'Amico E, Messina S, Caserta C, Patti F. A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. Expert Opin Drug Saf 2015:1-12
30. Rose JW, Burns JB, Bjorklund J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007;69(8):785-9
31. European Medicines Agency: "EPAR for Zenapax", 2007
32. Ursea R, Nussenblatt RB, Buggage R. "Wegener's Granulomatosis: A Patient Education Monograph prepared for the American Uveitis Society", National Institutes of Health Bethesda. 2003
33. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006;18(5):263-75
34. Kaveri SV, Mouthon L, Bayry J. Basophils and nephritis in lupus. N Engl J Med 2010;363(11):1080-2
35. Furie R, Petri M, Zamani O, et al. BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63(12):3918-30
36. Navarra SV, Guzmán RM, Gallacher AE, et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9767):721-31
37. National Cancer Institute: "Fresolimumab"; WHO Drug Information
38. Venkiteshwaran A. Tocilizumab. MAbs 2009;1(5):432-8
39. De Benedetti F, Brunner H, Ruperto N, Schneider R, et al. The Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: Results from the TENDER trial. Arthritis Rheumatol 2014
40. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional diseasemodifying antirheumatic drug therapy study. Arthritis Rheum 2008;58(10):2968-80
41. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an openlabel phase I dosage-escalation study. Arthritis Rheum 2010;62(2):542-52
42. Trimarchi H. Abatacept and glomerular diseases: the open road for the second signal as a new target is settled down. Recent Pat Endocr Metab Immune Drug Discov 2015. [Epub ahead of print]
43. Dall'Era M, Davis J. CTLA4Ig: a novel inhibitor of costimulation. Lupus 2004;13(5):372-6
44. Alkandari O, Nampoory N, Nair P, et al. Recurrent focal segmental glomerulosclerosis and abatacept: case report. Exp Clin Transplant 2014;doi: 10.6002/ect.2014.0154. [Epub ahead of print]
45. Yu CC, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013;369(25):2416-23
46. Lopez-Olivo MA, Kallen MA, Ortiz Z, et al. Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: a systematic review. Arthritis Rheum 2008;59(11):1625-38
47. Shah SB, Hanauer SB. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev Gastroenterol Disord 2008;8(3):159-68
48. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359(8):810-20
49. Li X, Magenheimer BS, Xia S, et al. A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med 2008;14(8):863-8
50. Lama G, Luongo I, Tirino G, et al. T-lymphocyte populations and cytokines in childhood nephrotic syndrome. Am J Kidney Dis 2002;39(5):958-65
51. Bakr A, Shokeir M, El-Chenawi F, et al. Tumor necrosis factor-alpha production from mononuclear cells in nephritic syndrome. Pediatr Nephrol 2003;18(6):516-20
52. Niemir ZI, Ondracek M, Dworacki G, et al. "In situ regulation of IL-10 reflects the activity of human glomerulonephritides". Am J Kid Dis 1998;32:80-92
53. McCarthy ET, Sharma R, Sharma M, et al. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 1998;9(3):433-8
54. Joy MS, Gipson DS, Powell L, et al. "Phase 1 trial of Adalimumab in focal segmental glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group". Am J Kidney Dis 2010;55:50-60
55. Santoro D, Postorino A, Costantino G, et al. Anti-TNF-A therapy in membranous glomerulonephritis. Clin Kidney J 2012;5:487-8
56. Campbell S, Michaelson J, Burkly L, Putterman C. The role of TWEAK/ Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 2004;9:2273-84
57. BIIB023 for subjects with Lupus Nephritis?". Mayo Clinc, IRB Number: 11-008028
58. Frolich D, Blassfeld D, Reiter K, et al. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. Arthritis Res Ther 2012;14(2):R54
59. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-b by anti-TGF-b antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45(4):522-30
60. van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2014;9(6):1066-73
61. Remuzzi G, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy. Lancet 2002;360:923-4
62. Lindholm C, Borjesson-Asp K, Zendjanchi K, et al. Long-term clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008;35:826-33
63. Radhakrishnan S, Lunn A, Kirschfink M, Ono S. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012;366:1165-6
64. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of densedeposit disease. N Engl J Med 2012;366:1163-5
65. Joy MS, Gipson DS, Powell L, et al. "Phase 1 trial of Adalimumab in focal segmental glomerulosclerosis (FSGS): II". Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis 2010;55:50-60
66. Trachtman H, Fervenza FC, Gipson DS, et al. "A phase 1, single-dose study of fresolimumab, an anti-TGF-b antibody, in treatment-resistant primary focal segmental glomerulosclerosis". Kidney Int 2011;79:1236-43
67. Yu C-C, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013;369:2416-23
68. Loiacono C, Sgroi C, Coppolino S, et al. How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011. BioDrugs 2012;26(2):113-20
69. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8
70. Fiorino G, Girolomoni G, Lapadula G, SIR, SIDeMaST, and IG-IBD. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev 2014;13(7):751-5